Oxford BioDynamics
Plc
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Result of
AGM
27 March 2024
- Oxford BioDynamics Plc (AIM: OBD, the
"Company"), a biotechnology company
developing precision medicine tests based on the EpiSwitch® 3D
genomics platform announces that all resolutions
proposed at the Company's Annual General Meeting, held earlier
today, were duly passed.
For further
details please contact:
|
Oxford BioDynamics
Plc
Jon
Burrows, CEO
Paul
Stockdale, CFO
|
+44
(0)1865 518910
|
|
Shore Capital - Nominated
Adviser and Broker
Advisory:
Stephane Auton / Iain Sexton
Broking:
Fiona Conroy
|
+44 (0)20
7408 4090
|
|
WG Partners - Joint
Broker
David
Wilson / Claes Spång / Sateesh Nadarajah
/ Erland Sternby
|
+44 (0)20
3705 9330
|
|
Instinctif
Partners
|
+44 (0)20
7457 2020
|
|
Melanie Toyne-Sewell / Jack
Kincade
|
OxfordBioDynamics@instinctif.com
|
Notes for
Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is
a global biotechnology company, advancing personalized healthcare
by developing and commercializing precision medicine tests for
life-changing diseases.
Its flagship products are
the EpiSwitch®
CiRT (Checkpoint Inhibitor
Response Test) and EpiSwitch®
PSE (EpiSwitch Prostate Screening
test) blood tests. CiRT is a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or
absence of prostate cancer, which was launched in the US and UK in
September 2023.
In March 2021, the Company launched
its first commercial prognostic test, EpiSwitch®
CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker
discovery, EpiSwitch®
Explorer Array Kit, which is available
for purchase by the life science research community.
The Company's product portfolio is
based on a proprietary 3D genomic biomarker platform, EpiSwitch®,
which can build molecular diagnostic classifiers for the prediction
of response to therapy, patient prognosis, disease diagnosis and
subtyping, and residual disease monitoring in a wide range of
indications.
Oxford BioDynamics has participated
in more than 40 partnerships with big pharma and leading
institutions including Pfizer, EMD Serono, Genentech, Roche,
Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.
The Company has created a valuable
technology portfolio, including biomarker arrays, molecular
diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of
millions of data points from over 15,000 samples in more than 30
human diseases.
OBD is headquartered in Oxford, UK
and is listed on AIM of the London Stock Exchange. It also has a
commercial office in Gaithersburg and a clinical laboratory in
Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.
For more information, please visit
the Company's website, www.oxfordbiodynamics.com,
or follow OBD on Twitter (@OxBioDynamics)
and LinkedIn.